| 产品描述: | CXCR 抑制剂;CXCR Inhibitors;;InformationSX-682 SX-682 is an orally bioavailable small-molecule allosteric inhibitor of CXCR1 and CXCR2 that blocks tumor MDSC recruitment and enhances T cell activation and antitumor immunity.TargetsCXCR1 ; CXCR2In vivoWhole tumor accumulation of CXCL1 in vivo in MOC1 and LLC tumors is significantly greater than oral mucosa and normal lung, respectively, and not diminished with SX-682 treatment. Plasma accumulation of CXCL1 is greater in tumor-bearing mice compared with naive for both models and increases following SX-682 treatment. Treatment of mice bearing MOC1 or LLC tumors with SX-682 beginning 10 or 20 days after tumor initiation does not alter CXCR1 or CXCR2 expression on tumor cells in vivo.[2] Following in vivo SX-682 treatment, tumor PMN-MDSC expression of cell surface TGF-β or superoxide dismutase 1/2 genes, responsible for the generation of H2O2, is not significantly altered.[3] |
| 体内研究: |
SX-682 (50 mg/kg;口服;周一至周五;每天两次) 观察到作为单一药物对 CRPC 进展的影响微弱至中等,但与 ICB 联合产生了强大的效果。 |
| 参考文献: |
1. Sun L, et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 2019 Apr 4;4(7). 2. Lu X, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017 Mar 30;543(7647):728-732. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.14 ml |
10.702 ml |
21.404 ml |
| 5 mM |
0.428 ml |
2.14 ml |
4.281 ml |
| 10 mM |
0.214 ml |
1.07 ml |
2.14 ml |
| 50 mM |
0.043 ml |
0.214 ml |
0.428 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |